[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cancer Tyrosine Kinase Inhibitors Market Explored by Kuick Research in Topical Report Now Available at MarketPublishers.com

19 Aug 2016 • by Natalie Aster

LONDON – The constantly increasing cancer prevalence worldwide and the expanding recognition of the commercial and therapeutic opportunities opened by novel oncology treatment options have provided key incentives for the pharmaceutical industry to drive the development of novel agents and cancer treatment options. To cope with the ever increasing world’s cancer burden, the cancer therapeutics is inclining towards the targeted drug therapy owing to the plenty of drawbacks associated with conventional chemotherapy.

Tyrosine kinases have the most important role in the modulation of growth factor signaling. During the past several years, the tyrosine kinase inhibitors (TKI) drug discovery has increased considerably. Together with the launch of novel drugs, new efficient approaches for the development of selective and potent inhibitors with desirable properties were established. At present, due to ongoing research and technological advancements, tyrosine kinase inhibitors are recognised as the biggest class of potential drug targets by the pharmaceutical industry.

The clinical pipeline of cancer TKI therapeutics is rather strong owing to which competitive product is anticipated to enter continuously in the worldwide market. Given the constantly rising cancer incidences, it has become necessary to make certain steps in order to introduce innovative TKI therapeutics in world’s market. In the years to come, products with high efficacy and safety levels together with minimized side effects are likely to be developed. Presently, different products are at various stages of clinical trials, they are likely to enter the market in the years ahead.

Topical report “Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020” by Kuick Research gives access to an in-depth overview of the cancer tyrosine kinase inhibitors (TKI) market. It contains a comprehensive introduction to TKIs, evaluates the advantage of TKIs in cancer treatment, explores the key applications of TKIs in cancer therapy and traces the historical development of the cancer TKI market. The research study gives a granular analysis of the cancer TKI pipeline, uncovers data on products at various stages of clinical trials as well as offers trustworthy data on 32 marketed drugs. Future forecasts are also at hand.

Other cutting-edge topical reports by Kuick Research are given in this catalogue.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest